3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
6
Sarcoma
5
Neoplasms
5
Rhabdomyosarcoma
4
Prostatic Neoplasms
4
Osteosarcoma
3
Breast Neoplasms
3
Sarcoma, Synovial
2
Sarcoma, Ewing
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neoplasm Metastasis
2
Lung Neoplasms
2
Head and Neck Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Hepatocellular
2
Adrenocortical Carcinoma
2
Wilms Tumor
1
Uveal Melanoma
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Retinoblastoma
1
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors, Primitive
1
Neuroectodermal Tumors
1
Neuroblastoma
1
Mesothelioma, Malignant
1
Liver Neoplasms
1
Liposarcoma
1
Interventions
Oxaliplatin
49
Fluorouracil
45
Leucovorin
42
Capecitabine
40
Irinotecan
31
Bevacizumab
31
Radiotherapy
24
Cetuximab
23
Radiation
13
Panitumumab
13
Folfox protocol
10
Surgical Procedures, Operative
9
IFL protocol
8
Radiotherapy, Intensity-Modulated
6
Magnetic Resonance Spectroscopy
6
aflibercept
5
Immunohistochemistry
5
Gene Expression Profiling
5
Chemotherapy, Adjuvant
5
Fluorodeoxyglucose F18
4
Floxuridine
4
Celecoxib
4
trifluridine tipiracil drug combination
3
dehydroftorafur
3
XELOX
3
Sorafenib
3
Ramucirumab
3
Neoadjuvant Therapy
3
Erlotinib Hydrochloride
3
Drug Therapy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Rectal Neoplasms
×
cixutumumab
×
Clear all
NCT00845039
2018-07-02
FC-4
Eli Lilly and Company
Phase 2
Terminated
4 enrolled
9 charts